Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pseudolysin, commonly referred to as LasB elastase, is a potent extracellular zinc metalloprotease and a primary virulence factor secreted by the opportunistic pathogen Pseudomonas aeruginosa [1, 9]. It plays a multifaceted role in infection by degrading a wide range of host proteins, including elastin, collagen, and laminin, which leads to extensive tissue damage and facilitates bacterial invasion [5, 7, 15]. Beyond structural degradation, LasB subverts the host immune system by cleaving immunoglobulins, complement components, and various cytokines, thereby promoting immune evasion and persistent colonization [3, 7, 8]. It is also implicated in the regulation of biofilm formation and the activation of other bacterial enzymes [1, 14]. Because LasB is secreted into the extracellular environment, it is an accessible therapeutic target that does not require drugs to penetrate the complex Gram-negative bacterial cell wall [2, 6]. Current drug development efforts focus on pathoblockers—small-molecule inhibitors like phosphonates and thiols—that aim to attenuate virulence and enhance the efficacy of conventional antibiotics without inducing the selective pressure associated with traditional bactericidal agents [1, 2, 4].
Inhibition of the zinc-dependent catalytic site of the metalloprotease to prevent the degradation of host tissues and immune components [1, 2, 5].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudolysin (LasB).